| FORM 990, PART I, LINE 8 |
PURSUANT TO THE CORONAVIRUS AID, RELIEF, AND ECONOMIC SECURITY (CARES) ACT, THE JOHNS HOPKINS HOSPITAL RECOGNIZED $3,754,037 OF FUNDING FROM THE PROVIDER RELIEF FUND ADMINISTERED BY THE HEALTH RESOURCES AND SERVICES ADMINISTRATION, AN AGENCY OF THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES DURING FY22. THIS AMOUNT HAS BEEN RECOGNIZED AS GRANT REVENUE ON PART I, LINE 8 OF THE ORGANIZATION'S FORM 990. |
| PART III, LINE 1 |
THE JOHNS HOPKINS HOSPITAL, FOUNDED IN 1889, AND THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, CREATED IN 1893, FORM THE NUCLEUS OF JOHNS HOPKINS MEDICINE, ONE OF THE WORLD'S PREMIER, INTEGRATED HEALTH SYSTEMS. AS THE TEACHING HOSPITAL AFFILIATED WITH THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, THE JOHNS HOPKINS HOSPITAL IS A WORLD-RENOWNED ACADEMIC MEDICAL CENTER THAT PROVIDES A COMPREHENSIVE RANGE OF STATE-OF-THE-ART TERTIARY AND QUATERNARY CARE. THE JOHNS HOPKINS HOSPITAL PROVIDES QUALITY MEDICAL HEALTH CARE REGARDLESS OF RACE, CREED, SEX, NATIONAL ORIGIN, HANDICAP, AGE, OR ABILITY TO PAY. IN KEEPING WITH THE HOSPITAL'S COMMITMENT TO SERVE ALL MEMBERS OF ITS COMMUNITY, FREE CARE AND/OR SUBSIDIZED CARE, CARE PROVIDED TO PERSONS COVERED BY GOVERNMENTAL PROGRAMS AT BELOW COST, AND HEALTH ACTIVITIES AND PROGRAMS TO SUPPORT THE COMMUNITY MEMBERS WILL BE CONSIDERED WHERE THE NEED AND/OR AN INDIVIDUAL'S INABILITY TO PAY COEXISTS. JHH PROVIDES CARE TO PERSONS COVERED BY GOVERNMENTAL PROGRAMS AT BELOW COST. RECOGNIZING ITS MISSION TO THE COMMUNITY, SERVICES ARE PROVIDED TO BOTH MEDICARE AND MEDICAID PATIENTS. TO THE EXTENT REIMBURSEMENT IS BELOW COST, JHH RECOGNIZES THESE AMOUNTS AS CHARITY CARE IN MEETING ITS MISSION TO THE ENTIRE COMMUNITY. |
| FORM 990, PART III, LINE 4A |
ONCOLOGY SINCE ITS INCEPTION IN 1973, THE SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER AT THE JOHNS HOPKINS HOSPITAL HAS BEEN DEDICATED TO BETTER UNDERSTANDING HUMAN CANCERS AND FINDING MORE EFFECTIVE TREATMENTS. FOR OVER FORTY YEARS THE KIMMEL CANCER CENTER HAS BEEN TURNING RESEARCH INTO RESULTS. FROM THE BEGINNING, KIMMEL CANCER CENTER LEADERS HAD A UNIQUE VISION OF WHAT OUR CANCER CENTER SHOULD BE. ITS HALLMARKS WERE INTERDISCIPLINARY COLLABORATION AND INNOVATION THAT TRANSCENDED THE ARTIFICIAL BOUNDARIES OF INDIVIDUAL DEPARTMENTS, LABORATORIES, AND CLINICS. OUR MISSION WAS TO RAPIDLY TRANSFER DISCOVERIES ABOUT CANCER FROM THE BENCH TO THE BEDSIDE. THAT FOCUS AND MISSION REMAINS UNCHANGED TODAY. WITH THE CONVERGENCE OF TECHNOLOGY, BRILLIANT SCIENTIFIC MINDS, AND THE COMMITMENT OF THOSE WHO HAVE FUNDED THESE DISCOVERIES, WE HAVE COME TO A TIME WHEN WE CAN BEGIN TO ALTER THE COURSE OF CANCER IN WAYS WE COULD ONLY IMAGINE FOUR DECADES AGO. THE JOHNS HOPKINS KIMMEL CANCER CENTER IS ONE OF THE NATION'S 41 COMPREHENSIVE CANCER CENTERS DESIGNATED BY THE NATIONAL CANCER INSTITUTE, AND ONE OF THE FIRST TO EARN THAT STATUS. RESEARCH LED BY ITS FACULTY IS AMONG THE MOST HIGHLY-CITED IN CANCER RESEARCH AND CLINICAL CARE. THE STRENGTH OF OUR RESEARCH AND TREATMENT PROGRAMS WAS RECOGNIZED EARLY ON BY THE NATIONAL CANCER INSTITUTE, BECOMING ONE OF THE FIRST TO EARN COMPREHENSIVE CANCER CENTER STATUS AND RECOGNITION AS A "CENTER OF EXCELLENCE." HOPKINS HAS PIONEERED FIELDS SUCH AS CANCER GENETICS, BONE MARROW TRANSPLANT MEDICINE AND CANCER IMMUNOTHERAPY. THE KIMMEL CANCER CENTER IS THE ONLY COMPREHENSIVE CANCER CENTER IN THE STATE OF MARYLAND. IT ENCOMPASSES A WIDE SPECTRUM OF SPECIALTY PROGRAMS FOR BOTH ADULTS AND CHILDREN COPING WITH CANCER, INCLUDING BONE MARROW TRANSPLANTATION AND NEW DRUG DEVELOPMENT. PATIENTS WHO VISIT THE KIMMEL CANCER CENTER HAVE ACCESS TO SOME OF THE MOST INNOVATIVE AND ADVANCED THERAPIES IN THE WORLD. BECAUSE KIMMEL CANCER CENTER RESEARCH SCIENTISTS AND CLINICIANS WORK CLOSELY TOGETHER, NEW DRUGS AND TREATMENTS DEVELOPED IN THE LABORATORY ARE QUICKLY TRANSFERRED TO THE CLINICAL SETTING, OFFERING PATIENTS CONSTANTLY IMPROVED THERAPEUTIC OPTIONS. THE KIMMEL CANCER CENTER'S BONE MARROW TRANSPLANT PROGRAM (BMT), HAS BEEN AN INTERNATIONALLY RENOWNED PROGRAM IN THE AREA OF BLOOD AND MARROW TRANSPLANTATION FOR MORE THAN 30 YEARS. IN THAT TIME, BMT HAS BECOME AN ACCEPTED, CURATIVE THERAPY FOR A BROAD RANGE OF DISEASES, INCLUDING MALIGNANT DISEASES THAT INVOLVE THE BONE MARROW SUCH AS LEUKEMIA AND LYMPHOMA, NONMALIGNANT DISEASES THAT INVOLVE THE BONE MARROW SUCH AS APLASTIC ANEMIA AND A VARIETY OF INHERITED DISEASES. TO DATE, MORE THAN 5,000 BONE MARROW TRANSPLANTS HAVE BEEN PERFORMED AT JOHNS HOPKINS, A NATIONAL CANCER INSTITUTE-DESIGNATED COMPREHENSIVE CANCER CENTER THAT IS FULLY ACCREDITED BY THE NATIONAL MARROW DONOR PROGRAM AS AN UNRELATED DONOR TRANSPLANT CENTER. AS A NATIONAL REFERRAL CENTER FOR BMT, HOPKINS PERFORMS AROUND 300 TRANSPLANTS EACH YEAR. THE WORK BY CENTER INVESTIGATORS IN CANCER GENETICS AND EPIGENETICS IS RECOGNIZED AS THE CLASSIC MODEL FOR DECIPHERING THE MECHANISMS OF CANCER INITIATION AND PROGRESSION. THE PIONEERING RESEARCH THAT DEFINED CANCER AS A GENETIC DISEASE WAS DONE AT OUR CENTER. THESE DISCOVERIES LED TO THE FIRST GENETIC TESTS FOR A HEREDITARY CANCER AND A SCREENING STOOL TEST FOR COLON CANCER. OUR INVESTIGATORS WERE THE FIRST TO MAP A CANCER GENOME, DECIPHERING THE GENETIC BLUEPRINTS FOR COLON, BREAST, PANCREATIC, AND BRAIN CANCERS. OF THE 75 CANCERS FOR WHICH ALL GENES HAVE BEEN SEQUENCED, 68 HAVE BEEN DONE AT THE KIMMEL CANCER CENTER. THESE DISCOVERIES HAVE PAVED THE WAY FOR PERSONALIZED THERAPIES WITH OUR INVESTIGATORS UNDERTAKING THE FIRST USE OF PERSONALIZED GENOME SCANNING TO REVEAL THE GENE MUTATION THAT CAUSED A PERSON'S INHERITED FORM OF PANCREATIC CANCER. |
| FORM 990, PART III, LINE 4B |
NEUROSURGERY THE DEPARTMENT OF NEUROSURGERY AT THE JOHNS HOPKINS HOSPITAL ("JHH") CONTINUES ITS MISSION TO IMPROVE THE LIVES OF PATIENTS BY BUILDING UPON A TRADITION OF DEEP COLLABORATION. THE DEPARTMENT IS COMPRISED OF OVER 20 FULL TIME CLINICAL NEUROSURGEONS THAT PROVIDE CARE TO OUR PATIENTS WITH THE HELP OF SPECIALIZED NURSES AND OTHER HEALTH CARE PROVIDERS IN THE OPERATING ROOMS, OUTPATIENT CLINICAL BUILDING, AND OUR INPATIENT CRITICAL CARE AND ACUTE CARE UNITS. THE SHEIKH ZAYED TOWER AND THE CHARLOTTE R. BLOOMBERG CHILDREN'S CENTER OFFER ENHANCED LEVELS OF NEUROLOGICAL AND NEUROSURGICAL CARE. THE OPENING OF THESE FACILITIES ENABLES JHH TO PROVIDE PATIENT-FOCUSED NEUROLOGICAL SERVICES INCLUDING STATE-OF-THE-ART ADULT AND PEDIATRIC OPERATING ROOMS THAT INCLUDE INTRA-OPERATIVE MRI MACHINES THAT PROVIDE REAL-TIME IMAGES OF THE BRAIN DURING SURGERY. IN ADDITION, OUR NEUROLOGICAL CRITICAL CARE UNIT ("NCCU") PROVIDES COMPLETE INTENSIVE CARE MANAGEMENT TO PATIENTS ADMITTED FROM NEUROSURGERY, NEUROLOGY, ORTHOPEDIC/SPINE, OTOLARYNGOLOGY AND PLASTIC SURGERY. OUR SURGEONS ARE ABLE TO BRING NEW AND EXCEPTIONAL TREATMENTS TO OUR ADULT AND PEDIATRIC PATIENTS FASTER BECAUSE OF OUR TIGHT NETWORK OF EXPERTS WHO SPECIALIZE IN CONDITIONS SUCH AS BRAIN TUMOR, CEREBROVASULAR DISEASE, FUNCTIONAL DISORDERS, PERIPHERAL NERVE CONDITIONS, SPINAL DEFORMITY, TUMORS AND REPAIR AND TRAUMA. WE OPERATE SEVERAL NEUROLOGICAL CENTERS OF CARE AT JOHNS HOPKINS HOSPITAL INCLUDING THE EPILEPSY CENTER AT JOHNS HOPKINS WHICH EVALUATES AND CARES FOR PATIENTS WITH SEIZURE DISORDERS FROM INFANTS THROUGH THE ELDERLY. A UNIQUE ASPECT OF OUR EPILEPSY CENTER IS THAT WE PROVIDE A CONTINUUM OF CARE FOR OUR PATIENTS ACROSS THE AGE SPECTRUM MAKING USE OF ENHANCED EPILEPSY MONITORING EQUIPMENT THAT IS SPECIFICALLY DESIGNED FOR THE EVALUATION OF ADULT AND PEDIATRIC SEIZURE DISORDERS. OUR COMPREHENSIVE BRAIN TUMOR CENTER IS ONE OF THE LARGEST BRAIN TUMOR TREATMENT AND RESEARCH CENTERS IN THE WORLD. WE TREAT AN EXTREMELY LARGE NUMBER OF PATIENTS AFFECTED BY ALL TYPES OF BRAIN TUMORS. WE TAILOR THE BEST AND MOST ADVANCED THERAPIES THAT EACH UNIQUE TUMOR DEMANDS. OUR TEAM CONSISTS OF SKILLED SURGEONS, NEUROLOGISTS AND ONCOLOGISTS THAT CAN PROVIDE THE MOST EFFECTIVE AND SAFEST TREATMENT EVEN ON THE MOST CHALLENGING TYPES OF TUMORS. PATIENTS COME TO JOHNS HOPKINS FOR NEUROLOGICAL CARE FROM THE LOCAL BALTIMORE COMMUNITY AND THE MID-ATLANTIC REGION AS WELL AS FROM AROUND THE NATION AND THE WORLD TO RECEIVE THE MOST CUTTING-EDGE CARE, AND FIND THAT WE ARE A PLACE OF HOPE AND CARE. EACH YEAR, WE PROVIDE OVER 30,000 OUTPATIENT CONSULTATIONS AND PERFORM MORE THAN 4,000 BRAIN, TUMOR, VASCULAR AND PERIPHERAL NERVE OPERATIONS IN THE JOHNS HOPKINS OUTPATIENT CENTER. IN OUR HOSPITAL, WE ALSO PROVIDED CARE TO OVER 3,000 ADULT AND 500 PEDIATRIC PATIENTS WITH NEUROSURGICAL DISEASES. JOHNS HOPKINS HAS EMERGED AS ONE OF THE MOST COMPREHENSIVE NEUROLOGICAL CENTERS OF ITS KIND AS RECOGNIZED BY OUR TOP THREE RANKING IN THE NATION IN NEUROLOGY AND NEUROSURGERY BY U.S. NEWS AND WORLD REPORT. |
| FORM 990, PART III, LINE 4C |
ADULT CARDIAC SURGERY-JOHNS HOPKINS MEDICINE JOHNS HOPKINS CARDIAC SURGEONS PROVIDE A FULL RANGE OF TRADITIONAL AND MINIMALLY INVASIVE CARDIAC SURGICAL SERVICES THROUGHOUT THE BALTIMORE AND WASHINGTON, D.C., METROPOLITAN AREAS. OUR EXPERTS PROVIDE CUTTING-EDGE TREATMENT AND PROCEDURES FOR PATIENTS WITH HEART AND VASCULAR DISEASES. THE TEAM HAS EXPERTISE IN AORTIC DISEASE, CONGENITAL CARDIAC SURGERY, CORONARY ARTERY BYPASS, HEART TRANSPLANT, MITRAL VALVE REPAIR AND REPLACEMENT, TRANSCATHETER AORTIC VALVE REPLACEMENT, VENTRICULAR ASSIST DEVICES, ECMO, AND SURGICAL ABLATION FOR ATRIAL FIBRILLATION. ADDITIONALLY, OUR TEAM COMPLETES GROUNDBREAKING RESEARCH, COMMITTED TO CONTINUALLY STUDYING AND EVALUATING NEW METHODS OF SURGICAL TREATMENT AND IMPROVING SURGICAL OUTCOMES THROUGH CLINICAL AND LABORATORY RESEARCH. AT OUR HEART AND VASCULAR INSTITUTE, WE ORGANIZE OUR CARDIOVASCULAR DISEASE CARE MODEL AROUND COLLABORATIVE MULTIDISCIPLINARY TEAMS TEAMS IN WHICH CARDIOLOGISTS, CARDIAC SURGEONS, ADVANCED PRACTITIONERS, ANESTHESIOLOGISTS AND OTHERS WORK HAND IN GLOVE WITH EXPERTS IN ENGINEERING, STATISTICS, DIGITAL TECHNOLOGY AND OTHER FIELDS TO PERSONALIZE HOW WE DIAGNOSE AND TREAT OUR PATIENTS. THIS KIND OF CLINICAL CREATIVITY, WHEN COMBINED WITH THE IMPRESSIVE DISCOVERIES OF OUR BASIC SCIENTISTS, COMPRISES AN EXCITING "THINK TANK" OF INNOVATORS AND IDEAS BASED RIGHT HERE AT JOHNS HOPKINS IDEAS THAT WILL LEAD TO PROGRESS AGAINST A FORMIDABLE DISEASE. |
| FORM 990, PART VI, SECTION A, LINE 2 |
1. WILLIAM CONWAY, JR. IS A TRUSTEE OF JOHNS HOPKINS MEDICINE, JOHNS HOPKINS HEALTH SYSTEM CORPORATION, AND THE JOHNS HOPKINS HOSPITAL. DAVID M. RUBENSTEIN IS A TRUSTEE OF JOHNS HOPKINS MEDICINE. MESSRS. CONWAY AND RUBENSTEIN HAVE A BUSINESS RELATIONSHIP. |
| FORM 990, PART VI, SECTION A, LINE 6 |
JOHNS HOPKINS HEALTH SYSTEM CORPORATION, A IRC 501(C)(3) TAX EXEMPT ORGANIZATION, IS THE SOLE CORPORATE MEMBER OF THE JOHNS HOPKINS HOSPITAL. |
| FORM 990, PART VI, SECTION A, LINE 7A |
JOHNS HOPKINS HEALTH SYSTEM CORPORATION, A IRC 501(C)(3) TAX EXEMPT PARENT ORGANIZATION OF THE JOHNS HOPKINS HOSPITAL ELECTS THE BOARD OF TRUSTEES. |
| FORM 990, PART VI, SECTION A, LINE 7B |
THE GOVERNING BODY OF THE JOHNS HOPKINS HOSPITAL IS EMPOWERED BY ITS BY-LAWS TO MAKE CERTAIN DECISIONS; ALL OTHER DECISIONS ARE SUBJECT TO APPROVAL OF THE PARENT ORGANIZATION JOHNS HOPKINS HEALTH SYSTEM CORPORATION. |
| FORM 990, PART VI, SECTION B, LINE 11B |
A COPY OF THE FORM 990 IS PROVIDED ELECTRONICALLY TO THE ORGANIZATION'S GOVERNING BODY BEFORE IT IS FILED. THE FORM 990 IS PROVIDED TO THE ORGANIZATION'S TRUSTEES AND APPROPRIATE OFFICERS, WHO ARE GIVEN THE OPPORTUNITY TO ASK QUESTIONS AND PROVIDE FEEDBACK BEFORE THE FORM 990 IS FILED. THE AUDIT COMMITTEE OF THE BOARD OF TRUSTEES OF THE ORGANIZATION MEETS ANNUALLY BEFORE THE FORM 990 IS FILED TO REVIEW THE FORM 990. AT THIS MEETING, THE JHHS TAX DEPARTMENT PRESENTS A SUMMARY OF THE FORM 990 TO THE AUDIT COMMITTEE AND THE ORGANIZATION CFO. |
| FORM 990, PART VI, SECTION B, LINE 12C |
THE CONFLICT OF INTEREST POLICY IS A PART OF THE ANNUAL DISCLOSURE STATEMENT PROCESS. ALL OFFICERS, DIRECTORS, TRUSTEES, AND KEY EMPLOYEES ARE REQUIRED TO REPORT ANY CONFLICTS OF INTEREST AND TO COMPLY WITH THE CONFLICT OF INTEREST POLICY. CONFLICTS OF INTEREST ARE DETERMINED AT A HEALTH SYSTEM LEVEL AND INCLUDE THE ORGANIZATION AND ALL OF ITS AFFILIATES. THE ORGANIZATION LEGAL DEPARTMENT IS RESPONSIBLE FOR REVIEWING ALL ACTUAL OR POTENTIAL CONFLICTS OF INTERESTS AND FOR DETERMINING APPROPRIATE ACTION TO ELIMINATE OR MANAGE THE CONFLICT OF INTEREST. IF A CONFLICT ARISES, THE AFFECTED MEMBER MUST (1) REFRAIN FROM ANY ATTEMPTS TO EITHER DIRECTLY OR INDIRECTLY INFLUENCE THE DECISION-MAKING PROCESS IN WHICH THERE EXISTS A POTENTIAL FOR CONFLICTS OF INTEREST; (2) REFRAIN FROM PARTICIPATING IN ANY DISCUSSIONS LEADING TO THE APPROVAL OR DISAPPROVAL OF THE TRANSACTION CREATING THE CONFLICT, EXCEPT TO DISCLOSE MATERIAL FACTS RELATING TO THE CONFLICT; AND (3) ABSTAIN FROM VOTING ON THE TRANSACTION CREATING THE CONFLICT OR TRANSMITTING ANY OTHER OPINION, INCLUDING NOT BEING PRESENT IN THE ROOM WHEN THE VOTE IS TAKEN, UNLESS THE VOTE IS BY SECRET BALLOT. FURTHERMORE, THE ORGANIZATION'S INTERMEDIATE SANCTIONS TRANSACTION REVIEW COMMITTEE REVIEWS AND DETERMINES WHETHER A PROPOSED TRANSACTION BETWEEN A TRUSTEE, OFFICER, KEY EMPLOYEE, OR DISQUALIFIED PERSON AND THE ORGANIZATION WOULD CREATE AN EXCESS BENEFIT TO SUCH TRUSTEE, OFFICER, KEY EMPLOYEE OR A DISQUALIFIED PERSON, OR WHETHER SUCH PROPOSED TRANSACTION QUALIFIES FOR A REBUTTABLE PRESUMPTION AGAINST EXCESS BENEFIT. |
| FORM 990, PART VI, SECTION B, LINE 15 |
THE COMPENSATION COMMITTEE OF THE BOARD OF JOHNS HOPKINS MEDICINE ("COMMITTEE") REVIEWS THE PERFORMANCE AND APPROVES THE COMPENSATION OF THE OFFICERS AND KEY PERSONNEL OF THE ORGANIZATION AND ITS SUBSIDIARIES. ON AN ANNUAL BASIS, THE COMMITTEE REVIEWS INDIVIDUAL COMPENSATION ARRANGEMENTS FOR ORGANIZATION SENIOR VICE PRESIDENT POSITIONS AND ABOVE, TOP AFFILIATE EXECUTIVES, CLINICAL DEPARTMENT DIRECTORS, OTHER EXECUTIVE POSITIONS WITH A BASE SALARY OF $500,000 OR GREATER AS WELL AS EXECUTIVE POSITIONS WHOSE TOTAL COMPENSATION EXCEEDS THE MARKET 90TH PERCENTILE. IN REVIEWING AND APPROVING COMPENSATION, THE COMMITTEE RELIES ON APPROPRIATE MARKET DATA (PROVIDED BY A THIRD-PARTY CONSULTANT) FOR COMPARABLE JOBS AND ORGANIZATIONS, AND ASSURES THAT SUCH DATA INDICATES THE COMPENSATION ORDINARILY PROVIDED BY SIMILARLY SITUATED ORGANIZATIONS, UNDER LIKE CIRCUMSTANCES. DELIBERATIONS AND DECISIONS OF THE COMMITTEE REGARDING THE COMPENSATION ARRANGEMENTS ARE DOCUMENTED IN THE FORM OF MINUTES OF COMMITTEE MEETINGS, AND COPIES OF ALL COMPARABILITY DATA AND REPORTS ARE RETAINED. |
| FORM 990, PART VI, SECTION C, LINE 19 |
INTERNAL POLICIES, INCLUDING CONFLICT OF INTEREST POLICY, ARE PROVIDED TO THE PUBLIC ON THE ORGANIZATION'S WEBSITE. FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST, THE GOVERNING DOCUMENTS HAVE BEEN MADE AVAILABLE IN THE PUBLIC FILING WITH THE STATE OF MARYLAND AND THE INTERNAL REVENUE SERVICE. |
| FORM 990, PART IX, LINE 11G |
CONTRACTED SERVICES: PROGRAM SERVICE EXPENSES 117,211,098. MANAGEMENT AND GENERAL EXPENSES 220,297,298. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 337,508,396. |
| FORM 990, PART XI, LINE 9: |
MINIMUM PENSION LIABILITY 189,008,007. CHANGE IN MKT VAL. OF SWAP AGREEMENT 81,363,614. NON-OPERATING SERVICES -19,767,167. OTHER COMPONENTS OF NET PERIODIC PENSION COST -22,223,004. TRANSFER BETWEEN AFFILIATES 3,277. CONTRIBUTIONS TO AFFILIATES -45,944,303. |
Attach to Form 990 or 990-EZ.